Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Academic Article uri icon

Overview

abstract

  • BACKGROUND: Level 1 evidence has demonstrated increased overall survival with cisplatin-based neoadjuvant chemotherapy for patients with muscle-invasive urothelial cancer. Usage remains low, however, in part because neoadjuvant chemotherapy will not be effective for every patient. To identify the patients most likely to benefit, we evaluated germline pharmacogenomic markers for association with neoadjuvant chemotherapy sensitivity in 2 large cohorts of patients with urothelial cancer. PATIENTS AND METHODS: Patients receiving neoadjuvant cisplatin-based chemotherapy for muscle-invasive urothelial cancer were eligible. Nine germline single nucleotide polymorphisms (SNPs) potentially conferring platinum sensitivity were tested for an association with a complete pathologic response to neoadjuvant chemotherapy (pT0) or elimination of muscle-invasive cancer (

publication date

  • March 10, 2016

Research

keywords

  • Antineoplastic Agents
  • Carcinoma, Transitional Cell
  • Cisplatin
  • Germ-Line Mutation
  • Polymorphism, Single Nucleotide

Identity

PubMed Central ID

  • PMC5018246

Scopus Document Identifier

  • 84963517143

Digital Object Identifier (DOI)

  • 10.1016/j.clgc.2016.03.006

PubMed ID

  • 27150640

Additional Document Info

volume

  • 14

issue

  • 6